Multiple myeloma (MM) survival continues to improve, but population-level data indicate that early mortality remains a substantial barrier to advances in MM outcomes. Recommendations are made for management may minimize the risk of early mortality and ensure that patients have the opportunity to benefit from the long-term impact of new effective MM agents, such as the early introduction of novel agents even in the presence of comorbidities and advanced age and aggressive management of MM-related complications.
Reference: Gonsalves, W, Godby, K, et al. Limiting early mortality: Do’s and don’ts in the management of patients with newly diagnosed multiple myeloma. American Journal of Hematology. 27 July 2015.